Many patients who are experiencing depressive episodes or anxiety disorders do not respond fully or partly to first and second line pharmacological, psychotherapeutic and other treatments. Treatment decisions for the further management of this patient group have been hampered by the lack of consensus in definition of what constitutes ‘treatment resistance’ – and indeed on whether that is the most appropriate term – and by difficulties inherent in remaining up-to-date with an emerging literature. There has been much recent interest in the possible effects of ketamine and related compounds on managing anxiety symptoms and disorders.
This session will consider optimal terminology contributors to treatment resistance in depression, the evidence-based management of treatment resistance in anxiety disorders, and the effects of (es)ketamine on anxiety symptoms, with the aim of informing clinical practice.
Learning objectives
In this session you will:
- Consider optimal terminology for treatment-resistance in patients with depressive illness and anxiety disorders
- Gain updated knowledge of the evidence base relating to treatment resistance in anxiety disorders.
Speakers
Dr Luca Sforzini, Institute of Psychiatry, Psychology and Neuroscience, Kings College, London
Dr Harry Fagan, University of Southampton Faculty of Medicine, Southampton
Dr Zoe Tebbs, Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton
Availability
This webinar is part of the Congress webinar 2025 package. If you attended all four days of Congress, you will have access to these as part of your Congress package. Otherwise the Congress webinar 2025 package can be purchased below.
